Login to Your Account


DUBLIN – Domain Therapeutics SA and Medixci Ventures have teamed up to form Mavalon Therapeutics SA, a single-asset play with €9 million (US$10 million) funding and a preclinical Parkinson's disease program.

PERTH, Australia – With another FDA approval in hand for its regenerative tissue portfolio, Brisbane, Australia-based Admedus Ltd. said it expects to become profitable in the next 12 to 18 months.

Earlier this year, the quiet joining of two recent San Diego-based startups led to the creation of Oncternal Therapeutics Inc., an oncology-focused firm boasting two potentially first-in-class drugs, both of which already have entered the clinic.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: